Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
about
Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
P2860
Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Augmentation of the anticancer ...... er by inhibiting Src activity.
@ast
Augmentation of the anticancer ...... er by inhibiting Src activity.
@en
type
label
Augmentation of the anticancer ...... er by inhibiting Src activity.
@ast
Augmentation of the anticancer ...... er by inhibiting Src activity.
@en
prefLabel
Augmentation of the anticancer ...... er by inhibiting Src activity.
@ast
Augmentation of the anticancer ...... er by inhibiting Src activity.
@en
P2093
P2860
P1476
Augmentation of the anticancer ...... cer by inhibiting Src activity
@en
P2093
P2860
P2888
P356
10.1186/S13045-017-0485-0
P407
P50
P577
2017-06-12T00:00:00Z
P6179
1085985725